EP 1278502 A2 20030129 - PROTEASE INHIBITORS
Title (en)
PROTEASE INHIBITORS
Title (de)
PROTEASE INHIBITOREN
Title (fr)
INHIBITEURS A PROTEASE
Publication
Application
Priority
- US 0112326 W 20010417
- US 19849300 P 20000418
- US 27381101 P 20010307
Abstract (en)
[origin: WO0189451A2] The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.
IPC 1-7
IPC 8 full level
A61K 31/55 (2006.01); C07D 491/048 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 5/14 (2006.01); A61P 7/00 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01); A61P 9/10 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 19/02 (2006.01); A61P 19/04 (2006.01); A61P 21/04 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01); C07D 223/08 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 421/14 (2006.01); C07D 491/04 (2006.01); C07D 495/04 (2006.01)
CPC (source: EP KR)
A61K 31/55 (2013.01 - KR); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 5/14 (2018.01 - EP); A61P 7/00 (2018.01 - EP); A61P 7/04 (2018.01 - EP); A61P 7/06 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/02 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/04 (2018.01 - EP); A61P 21/04 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 223/08 (2013.01 - EP); C07D 401/12 (2013.01 - EP); C07D 405/12 (2013.01 - EP); C07D 405/14 (2013.01 - EP); C07D 409/12 (2013.01 - EP); C07D 409/14 (2013.01 - EP); C07D 417/14 (2013.01 - EP); C07D 421/14 (2013.01 - EP); C07D 491/04 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0189451 A2 20011129; WO 0189451 A3 20020404; AR 032319 A1 20031105; AU 9050701 A 20011203; BR 0108954 A 20060509; CA 2406829 A1 20011129; CN 1431904 A 20030723; CO 5280088 A1 20030530; CZ 20023460 A3 20040317; EP 1278502 A2 20030129; EP 1278502 A4 20030521; HK 1053785 A1 20031107; HU P0301781 A2 20030929; IL 151087 A0 20030410; JP 2004526662 A 20040902; KR 20020089482 A 20021129; MX PA02010276 A 20030425; NO 20025005 D0 20021017; NO 20025005 L 20021206; PL 366040 A1 20050124
DOCDB simple family (application)
US 0112326 W 20010417; AR P010101786 A 20010417; AU 9050701 A 20010417; BR 0108954 A 20010417; CA 2406829 A 20010417; CN 01808290 A 20010417; CO 01029287 A 20010416; CZ 20023460 A 20010417; EP 01970508 A 20010417; HK 03104420 A 20030619; HU P0301781 A 20010417; IL 15108701 A 20010417; JP 2001585697 A 20010417; KR 20027013896 A 20021017; MX PA02010276 A 20010417; NO 20025005 A 20021017; PL 36604001 A 20010417